Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 study of MYMD-1 for treatment of rheumatoid arthritis

Next Previous
Trial Profile

Phase 2 study of MYMD-1 for treatment of rheumatoid arthritis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isomyosamine (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use

Most Recent Events

  • 22 Jul 2024 According to TNF Pharmaceuticals media release, MyMD Pharmaceuticals, Inc changed its name to TNF Pharmaceuticals, Inc.
  • 06 Dec 2023 According to a MyMD Pharmaceuticals media release, the Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1 as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA).
  • 06 Dec 2023 According to a MyMD Pharmaceuticals media release, Company plans to initiate this trial in the first quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top